Counterfeits Hamper ED Sales In Huge China Market
This article was originally published in PharmAsia News
Counterfeit copies of the three leading erectile dysfunction drugs are hindering the effort by major pharmaceutical companies to compete in that market in China. Despite a Chinese court case won by Pfizer last year upholding its patent for Viagra (sildenafil), drug makers find their sales are not keeping pace with the 30 percent increase in the Chinese market. Few men in a country with 20 percent of the world's population buy the real ED drugs because cheap copies are readily available. Eli Lilly, maker of Cialis (tadalafil) reports only 1 percent of its global sales comes from China. (Click here for more
You may also be interested in...
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.